<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335347">
  <stage>Registered</stage>
  <submitdate>22/04/2010</submitdate>
  <approvaldate>28/04/2010</approvaldate>
  <actrnumber>ACTRN12610000341022</actrnumber>
  <trial_identification>
    <studytitle>Lifestyle Management of Weight and Heart Disease Risk Factors in General Practice Patients</studytitle>
    <scientifictitle>Piloting a structured comprehensive lifestyle program ,CLIP ,delivered via telephone on weight loss and lipid profile in overweight and obese general practice patients.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The CLIP handbook will be posted to the participant ,plus telephone coaching will be provided by the National Heart Foundation Healthy Heart Information call centre staff alongside usual general practitioner (GP)care.The coaching and introduction for each participant will take approximately 20 or 30 minutes. They will be contacted by a CLIP trained coach for an introduction to the program and will be subsequently supported by them by telephone every 2 weeks for 12 weeks.</interventions>
    <comparator>Lifescripts resources are based on weight,nutrition and healthy lifestyle.It will be posted to the participant in week 1 to be used at the participants discretion over the 12 weeks of the study.Lifescripts is a national initiative, being implemented through local divisions of general practice.</comparator>
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A reduction in weight .The volunteers will be weighed at week 1 and the again at week 12.</outcome>
      <timepoint>week 1 and week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>A reduction in low density lipoprotein (LDL) cholesterol.This will be measured by obtaining a fasting blood sample by trained nursing staff at week 1 and  again at week 12.</outcome>
      <timepoint>week 1 and week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Questionnaires  on health wellbeing and exercise will be used to identify key patient characteristics, barriers and facilitators of successful short term dietary and exercise compliance.  The questionnaires will take approximately 30 minutes to complete at week 1 and week 12.</outcome>
      <timepoint>week 1 and week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age 30-55 years, Body Mass Index between 26 and 40 kg/m2
or a waist circumference greater than 102cm for men and greater than 88cm for women.Have at least one additional cardiovascular or diabetes risk factor including family history of cardiovascular disease or type 2 diabetes, family history of premature heart disease or hypercholesterolemia.
Walk independently and able to perform physical activity without pain.
No personal history of cardiac abnormalities.
Contactable by telephone
Able to tolerate particular foods such as fish and whole grains.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Reported medical treatment which GP indicates necessitates preclusion from study.Type 1  Diabetes .Lipid lowering medication ,for example Lipitor or Zocor.
Concurrent use of medications which may be adversely affected by the intervention for example Warfarin.
Existing chronic diseases like  diabetes, ischemic heart disease and asthma.
Women who are pregnant or breastfeeding
Patients who have a terminal illness ,cancer.
Patients deemed by their GP as not able to comply with the requirements of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>27/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Commonwealth Scientific Industrial Research Organisation</primarysponsorname>
    <primarysponsoraddress>Gate 13,Kintore Ave 
Adelaide BC SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Commonwealth Scientific Industrial Research Organisation</fundingname>
      <fundingaddress>Gate 13,Kintore Ave 
Adelaide BC SA 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Commonwealth Scientific Industrial Research Organisation</fundingname>
      <fundingaddress>Gate 13,Kintore Ave 
Adelaide BC SA 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress>Nil</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Manny Noakes</name>
      <address>Gate 13,Kintore Ave
Adelaide SA 5000</address>
      <phone>+61 08 83038827</phone>
      <fax />
      <email>manny.noakes@csiro.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Manny Noakes</name>
      <address>Gate 13,Kintore Ave
Adelaide SA 5000</address>
      <phone>+61 08 83038827</phone>
      <fax />
      <email>manny.noakes@csiro.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>